EE470 The Impact of a Cost Savings Cap on the Cost Effectiveness of Valoctocogene Roxaparvovec for the Treatment of Hemophilia A in the United States
Abstract
Authors
J Sarker JA Tice B. Herce-Hagiwara S.M. Fahim J Chu F Agboola S Pearson D.M. Rind S.M. Walton